- Home
- THC vs UTHR Comparison
THC vs UTHR Comparison
Compare THC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THC
- UTHR
- Stock Information
- Founded
- THC 1967
- UTHR 1996
- Country
- THC United States
- UTHR United States
- Employees
- THC N/A
- UTHR N/A
- Industry
- THC Hospital/Nursing Management
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- THC Health Care
- UTHR Health Care
- Exchange
- THC Nasdaq
- UTHR Nasdaq
- Market Cap
- THC 15.7B
- UTHR 13.8B
- IPO Year
- THC N/A
- UTHR 1999
- Fundamental
- Price
- THC $180.23
- UTHR $305.38
- Analyst Decision
- THC Buy
- UTHR Buy
- Analyst Count
- THC 17
- UTHR 13
- Target Price
- THC $193.44
- UTHR $382.00
- AVG Volume (30 Days)
- THC 967.0K
- UTHR 750.2K
- Earning Date
- THC 07-22-2025
- UTHR 07-30-2025
- Dividend Yield
- THC N/A
- UTHR N/A
- EPS Growth
- THC N/A
- UTHR 17.94
- EPS
- THC 15.65
- UTHR 25.63
- Revenue
- THC $20,683,000,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- THC $3.11
- UTHR $14.37
- Revenue Next Year
- THC $4.42
- UTHR $6.59
- P/E Ratio
- THC $11.49
- UTHR $11.91
- Revenue Growth
- THC N/A
- UTHR 17.62
- 52 Week Low
- THC $109.82
- UTHR $266.98
- 52 Week High
- THC $185.25
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- THC 64.33
- UTHR 51.55
- Support Level
- THC $177.36
- UTHR $303.59
- Resistance Level
- THC $182.90
- UTHR $315.73
- Average True Range (ATR)
- THC 3.88
- UTHR 7.31
- MACD
- THC 1.67
- UTHR 0.31
- Stochastic Oscillator
- THC 88.92
- UTHR 52.22
About THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.